Home Featured Page 174

Featured

Latest

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

Evelyn Eddy Shoop MSN, APRN, PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Dr Jason Konner – Psychedelic Oncology and the Future of Cancer Care

The Psychedelic News Feed: November 3 – 9, 2025

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1...

PT307 – Kathryn L. Tucker, JD – The Right to Try...

Health Canada Approves First Special Access Program Requests for Psilocybin

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1,...

Canada’s SAP Expansion Signals a Step Forward for Psychedelics

PT306 – Dr. Devon Christie – Vital Psychedelic Conversations

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides...

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects...

1...173174175...302 Page 174 of 302

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting...

Evelyn Eddy Shoop MSN, APRN, PMHNP-BC: Lived Experience, Qualitative Data, and...

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.